Journal
INFLAMMATORY BOWEL DISEASES
Volume 17, Issue 5, Pages 1229-1245Publisher
OXFORD UNIV PRESS INC
DOI: 10.1002/ibd.21557
Keywords
small molecules; therapeutics; biologics; cytokines; cell-based therapy; T-cells; regulatory T-cells; blood flow
Categories
Funding
- NIH [PO1-DK43785, 1]
Ask authors/readers for more resources
Most therapeutic agents used in clinical practice today were originally developed and tested in animal models so that drug toxicity and safety, dose-responses, and efficacy could be determined. Retrospective analyses of preclinical intervention studies using animal models of different diseases demonstrate that only a small percentage of the interventions reporting promising effects translate to clinical efficacy. The failure to translate therapeutic efficacy from bench to bedside may be due, in part, to shortcomings in the design of the clinical studies; however, it is becoming clear that much of the problem resides within the preclinical studies. One potential strategy for improving our ability to identify new therapeutics that may have a reasonable chance of success in clinical trials is to identify the most immunologically-relevant mouse models of IBD and pharmacologic strategies that most closely mimic the clinical situation. This review presents a critical evaluation of the different mouse models and pharmacological approaches that may be used in intervention studies as well as discuss emerging issues related to study design and data interpretation of preclinical studies. (Inflamm Bowel Dis 2011;17:1229-1245)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available